PolyTherics Receives a Technology Strategy Board Grant to Develop Fusion Proteins
News Apr 26, 2010
PolyTherics Limited has announced that it has started work on a Technology Strategy Board (TSB) funded project to produce fusion proteins using its chemical linker technologies.
PolyTherics will chemically fuse different but complementary proteins using its proprietary polyethylene glycol (PEG) linkers. The goal of the project is to develop a way of fusing proteins that is both quicker and cheaper than producing a fusion protein using recombinant techniques whilst retaining the different functions of both proteins. This will allow for rapid generation of a range of new fusion proteins for screening for a range of uses in a variety of industries, including as potential therapeutic products.
As PolyTherics’ PEGylation technologies enable the PEG to be attached to a specific site on a protein, either on the histidine residues added to facilitate its purification, or at a naturally occurring disulfide, the effect of the PEG on the function of the protein can be minimized. In addition, PEG is known to protect proteins from breakdown by proteases and thus improve their stability, a potential advantage over recombinant fusion proteins.
Reversing an Unstoppable Cancer Cascade with ProteomicsNews
Mutations in genes that produce RAS proteins turn a normally benign process, essential for cellular growth, into a cancer stimulant that is currently undruggable. Now, cutting-edge protein analysis may help treat cancers caused by these mutations.READ MORE
The Protein and the PauparNews
Non-coding RNAs (ncRNA) exist in a limbo within cells, having been created from genes but never destined to be turned into functional protein. A ncRNA called Paupar has been shown to regulate a protein controlling brain growth, a first for these mysterious molecules.READ MORE
Large Accumulation of ALS Protein Fibrils Not ToxicNews
Scientists have made a significant advance in the understanding of the complex and fatal neurodegenerative disease amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018